New KEYTRUDA® (Pembrolizumab) Data Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer Merck announced that new and updated data investigating KEYTRUDA®, the company’s anti-PD-1 therapy, in more than 15 types of cancer will be presented. [Press release from Merck & Co., Inc. discussing research to be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Incyte Highlights Jakafi® (Ruxolitinib) and Capmatinib Abstracts to Be Presented Incyte Corporation announced that more than 20 abstracts featuring its clinical development candidates will be presented. [Press release from Incyte Corporation discussing research to be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago and the European Hematology Association (EHA) Annual Meeting, Copenhagen] Press Release Chugai to Present Japanese Phase III Results on Alecensa® Chugai Pharmaceutical Co., Ltd. announced that the results of the Japanese Phase III study of Alecensa®, in ALK fusion gene positive non-small cell lung cancer patients, will be presented. [Press release from Chugai Pharmaceutical Co., Ltd. discussing research to be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Two-Year Overall Survival Data from Two Pivotal Opdivo® (Nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer Bristol-Myers Squibb Company announced two-year overall survival data from two pivotal Phase III studies evaluating Opdivo versus docetaxel in previously treated metastatic non-small cell lung cancer. [Press release from Bristol-Myers Squibb Company discussing research to be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers Merck KGaA and Pfizer announced that avelumab presentations across seven different tumor types, including two oral presentations, will be featured. [Press release from Pfizer Inc. discussing research to be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Phase III Study of Genentech’s Alecensa® (Alectinib) Showed Superior Efficacy versus Crizotinib in Japanese People with a Specific Type of Lung Cancer Genentech announced that Alecensa®, an oral anaplastic lymphoma kinase (ALK) inhibitor, reduced the risk of disease worsening or death by 66 percent compared to crizotinib in Japanese people with advanced or recurrent, ALK-positive NSCLC. [Press release from Genentech, Inc. discussing research to be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer Oncolytics Biotech Inc. announced preliminary data from a randomized, Phase II clinical study of REOLYSIN®. [Press release from Oncolytics Biotech Inc. discussing research to be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release AbbVie Demonstrates Progress in Oncology Research with Multiple Abstracts Evaluating Eight Medicines across Cancer Types AbbVie will present data from multiple clinical trials evaluating the company’s portfolio of approved and investigational oncology medicines. [Press release from AbbVie discussing research to be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Novartis to Present Pivotal Data in Hematologic and Solid Tumor Cancers Novartis will highlight the strength of its oncology research programs. Data will demonstrate advances across several of the company’s core disease areas of focus including leukemias and lung, melanoma and breast cancers. [Press release from Novartis AG discussing research to be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Data Underscore Lilly’s Diverse Oncology Pipeline and Portfolio Several studies will underscore the strength of Eli Lilly and Company’s diverse clinical cancer pipeline and portfolio. [Press release from Eli Lilly and Company discussing research to be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release From our sponsor: Learn how to form and isolate neural rosettes more efficiently. Watch the video. |